483
Frantisek Duska, M.D.FDA 483 - Frantisek Duska, M.D. - August 22, 2025
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
Record Details
An FDA inspection of Frantisek Duska, M.D., a clinical investigator in Prague, Czechia, revealed significant deficiencies in the conduct of study protocol 995 AdFirst. Observations included failures to maintain complete source documentation for adverse events and to report some adverse events, as well as incorrect calculation of blood loss as outlined in the investigational plan. These findings indicate a lack of adherence to proper clinical trial practices.
Open in Dashboard
ID · e4047880-01a1-4a7c-9374-204480719b51